Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy o...
March 07 2019 - 7:30AM
Company will present two posters on CNTX-4975 for
treatment of moderate to severe knee osteoarthritis
pain;pharmacological data from preclinical and Phase 1 and 2
clinical trials describing the mechanism of action; and
efficacy,safety and pharmacokinetic profile from late-stage
clinical trials
Centrexion Therapeutics Corporation, a company focused on
developing non-opioid, non-addictive therapeutics for the treatment
of chronic pain, today announced it will present two posters on
CNTX-4975 at the 35th Annual American Academy of Pain Medicine
(AAPM) Meeting taking place March 6-10, 2019 at the Colorado
Convention Center in Denver, Colorado. The presentations will
include preclinical through late-stage data on the efficacy,
safety/tolerability and pharmacokinetics from numerous animal and
human studies of the intra-articular injection of CNTX-4975 for
treatment of moderate to severe knee osteoarthritis pain.
In the poster entitled “Characterization of the Pharmacology of
CNTX-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical
Development for the Treatment of Moderate to Severe OA Knee Pain”,
the analysis of data compiled from preclinical through Phase 1 and
2 clinical trials demonstrate that CNTX-4975 has minimal off target
receptor activity at the 1mg dose, which is the dose used in the
ongoing Phase 3 clinical trials. Additionally, CNTX-4975 has
demonstrated substantial and prolonged pain reduction lasting up to
six months after a single treatment, with onset of activity by the
second day and significant at week 1, and an overall safety profile
similar to placebo in multiple preclinical and clinical
studies.
In the poster entitled “Pharmacokinetics of CNTX-4975, a
High-Purity, Synthetic Trans-Capsaicin in Clinical Development for
the Treatment of Moderate to Severe Osteoarthritis Knee Pain”, the
analysis of data compiled from multiple clinical studies
demonstrate that CNTX-4975 intra-articular knee injection was
rapidly absorbed, and also rapidly metabolized, in patients with
knee osteoarthritis pain.
“The duality of CNTX-4975 lies in its pharmacokinetics – with
fast absorption, short half-life and no detectable systemic
exposure by 24 hours after injection – while having the ability to
deactivate a portion of pain nerves in order to provide a prolonged
effect on pain relief, lasting up to six months,” said Randall
Stevens, M.D., chief medical officer at Centrexion. “We look
forward to presenting our data at AAPM and continuing to add to our
body of research for CNTX-4975.”
Full abstracts are available online at
http://www.painmed.org/2018scientific-abstracts/. Details of the
poster presentations are listed below.
Title #640: Characterization of the
Pharmacology of CNTX-4975, a High-Purity, Synthetic Trans-Capsaicin
in Clinical Development for the Treatment of Moderate to Severe OA
Knee Pain Session Title: AAPM35 Welcome
ReceptionPoster Number: 149Presentation
Time: Thursday, March 7, 6PM-7:30PM MST and Friday, March
8, 6PM-7:30PM MSTLocation: AAPM Resource Center in
the Colorado Convention Center – Mile High Ballroom
Title #555: Pharmacokinetics of CNTX-4975, a
High-Purity, Synthetic Trans-Capsaicin in Clinical Development for
the Treatment of Moderate to Severe Osteoarthritis Knee
PainSession Title: AAPM35
Welcome ReceptionPoster Number: 140
Presentation Time: Thursday, March 7, 6PM-7:30PM
MST and Friday, March 8, 6PM-7:30PM MSTLocation:
AAPM Resource Center in the Colorado Convention Center – Mile High
Ballroom
About Osteoarthritis Osteoarthritis (“OA”) is
the most common joint disease in the United States, currently
affecting more than 30 million Americans, according to the U.S.
Centers for Disease Control. OA occurs when cartilage, the tissue
that envelops the structural bones within a joint, gradually
deteriorates. These changes cause pain, swelling and problems
moving the joint. Although OA can affect any joint, it most often
affects joints in the knees, hips, lower back and neck, small
joints of the fingers and the bases of the thumb and big toe. Over
time, patients with knee OA tend to become inactive due to pain and
joint stiffness and reduced function.
About CNTX-4975 CNTX-4975, Centrexion’s most
advanced product candidate, is an investigational synthetic,
ultra-pure intra-articular injection of trans-capsaicin for the
treatment of moderate to severe pain associated with knee OA.
CNTX-4975 is designed to be administered directly into the joint
where the pain stimulus originates and to selectively and locally
target and disrupt the signaling of pain-sensing nerve fibers. In
January 2018, CNTX-4975 was granted Fast Track Designation by the
U.S. Food and Drug Administration for the treatment of pain
associated with knee OA.
About Centrexion TherapeuticsCentrexion is a
late clinical-stage biopharmaceutical company focused on becoming
the leader in identifying, developing and commercializing novel,
non-opioid and non-addictive therapies to address the large unmet
medical need for the treatment of chronic pain. Centrexion’s
website address is http://www.centrexion.com.
Deshpande, B., et al. Number of Persons With Symptomatic Knee
Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex,
and Obesity. Arthritis Care & Research. Published online
November 3, 2016
Media Contact Julie Normart, W2O pure +1 (559)
974-3245 jnormart@w2ogroup.com
Investor Contact Courtney Dugan, W2O pure +1
(212) 257-6723 cdugan@w2ogroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From May 2024 to Jun 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2023 to Jun 2024